You are here: Home » International » News » Companies
Business Standard

J&J seeking 20,000 Covid vaccine trial volunteers in hard-hit Latin America

Josue Bacaltchuk said countries hosting the trials would also likely get preferential access to vaccines once ready

Topics
Coronavirus | Coronavirus Vaccine | Johnson and Johnson

Reuters  |  SANTIAGO 

Johnson & Johnson
Johnson & Johnson

By Aislinn Laing

SANTIAGO (Reuters) - Johnson & Johnson will seek 20,000 volunteers for late-stage human trials of its experimental vaccine in hard-hit Latin America, one-third of the planned global total, one of its public health chiefs in the region said.

Josue Bacaltchuk, vice president of medical affairs for Latin America for Janssen, J&J's Belgian unit developing the vaccine prototype, said countries hosting the trials would also likely get preferential access to vaccines once ready.

"We expect the majority in Brazil because it's the biggest country and also the one most affected by the pandemic so we expect a lot of people volunteering, but we expect also high numbers in Colombia and in Argentina," Bacaltchuk said.

"It's the intention of the company to prioritize the countries that contribute to the development of the vaccine and that will have patients participating in the trials, yes," he added in an interview with Reuters on Thursday.

J&J's vaccine is one of over a hundred worldwide being developed in response to the pandemic, which has infected nearly 26.5 million people and led to some 869,323 deaths. Latin America has become the epicenter of the pandemic.

The drugmaker is carrying out tests in the United States and Belgium, and has added Chile, Argentina and Peru to a list of Latin American countries where it plans to conduct Phase III trials along with Brazil, Colombia and Mexico.

Its trials globally will include 60,000 volunteers.

The Latin American countries all have high infection numbers, making them attractive testing sites for vaccine developers since it is easier to obtain dependable trial results in areas with high rates of active transmission and infection.

Bacaltchuk said the decision to spread trials so widely was motivated in part by the challenge of securing sufficient volunteer numbers in a region crowded with other pharmaceutical conducting trials of their own prototypes.

"I think this is a potential risk and that's why we are going to a number of centers that is higher than the other to cover geographies that are not covered by the other studies," he said.

He said the response from volunteers in the region has been "quite positive" which he hoped would continue.

"This is impacting everybody and it's going to continue to impact even after this is over, the consequences will continue so we need to try and stop it as early as possible," he said.

 

(Reporting by Aislinn Laing in Santiago; Editing by Adam Jourdan and Matthew Lewis)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, September 05 2020. 08:36 IST
RECOMMENDED FOR YOU
.